Patient-Derived Xenograft Models of Human Cancer

1. Auflage 2017
ISBN: 978-3-319-55824-0
Verlag: Springer International Publishing

Buch, Englisch, 204 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 4489 g

Reihe: Molecular and Translational Medicine

This book provides a comprehensive, state-of-the-art review of PDX cancer models. In separately produced chapters, the history and evolution of PDX models is reviewed, methods of PDX model development are compared in detail, characteristics of available established models are presented, current applications are summarized and new perspectives about use of PDX models are proposed. Each chapter is written by a world-renowned expert who is conducting cutting-edge research in the field. Each of the subsections provide a comprehensive review of existing literature addressing the particular topic followed by a conclusive paragraph detailing future directions. Extensive illustrations make this an interactive text. 
Patient-Derived Xenograft Models of Human Cancer will serve as a highly useful resource for researchers and clinicians dealing with, or interested in, this important topic. It will provide a concise yet comprehensive summary of the current status of the field that will help guide preclinical and clinical applications as well as stimulate investigative efforts. This book will propagate innovative concepts and prompt the development of ground-breaking technological solutions in this field.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Wang, Yuzhuo

Gout, Peter W.

Lin, Dong

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

Section I: Introduction
History and Evolution of PDX Cancer Models
Section II: Establishment and Characterization of PDX Models
Methods of Generating PDX Models
Fidelity and Stability of PDX Models
Section III: Applications of PDX Models
Studies of Cancer Heterogeneity
PDX and Cancer Stem Cells
Modeling Cancer Metastasis
Modeling Drug Resistance
PDX and Biomarker Development
PDX and Preclinical Drug Screening
Co-clinical Trials and Personalized Cancer Therapy/Precision Medicine
Section IV: Epilogue
Future Perspective.

Über Autor(innen)

Yuzhuo Wang, PhDDirector, Living Tumor LaboratoryDistinguished Scientist, BC Cancer AgencySenior Scientist, Vancouver Prostate CentreProfessor, University of British Columbia675 West 10th Avenue, Room 3.122Vancouver, BC, Canada V5Z 1L3

Dong Lin, PhD, MDResearch Pathologist, Living Tumor Laboratory
Peter W. Gout, PhDScientific Consultant, Living Tumor LaboratoryHonorary Associate Professor, Department of Urologic Sciences, University of British ColumbiaEmeritus Senior Scientist, Department of Experimental Therapeutics, BC Cancer Agency<675 West 10th Avenue, Room 5.108Vancouver, BC, Canada V5Z 1L3